Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Indeed, patients with a high LSC17 score were less likely to achieve MRD-negative remission regardless of the treatment regimen received, although this did not reach statistical significance in the smaller group of patients treated with FLAG-Ida ( Online Supplementary Table S5 ; 30/52 [58%] vs . 54/59 [92%]; P <0.0001 for 7+3; 8/18 [44%] vs . 9/11 [82%]; P =0.06 for FLAG-Ida).

also in 111,027 other papers

For RFS, this difference was statistically significant in the intermediate group ( Online Supplementary Figure S5 ; P =0.02; HR=2.66; 95% CI: 1.16-6.1), while trending towards significance in the other groups.

also in 515 other papers